Cytiva and Veeda Lifesciences Establish Host Cell Protein Analysis Center in India to Support Biopharmaceutical Development
Key Insights
Cytiva (search) and Veeda Lifesciences (search) have partnered to launch a dedicated Host Cell Protein (search) Services Center in Bengaluru, India, focused on impurity analysis and HCP testing for biologics (search) manufacturers.
The center will provide regulatory-ready analytical services using advanced techniques including multiple attribute DIGE and mass spectrometry to detect trace-level impurities that could compromise product quality and patient safety.
This collaboration addresses growing industry demand for analytical tools that improve regulatory compliance and process control, supporting India's bioeconomy growth toward the USD 300 billion target by 2030.
Cytiva (search), a Danaher (search) company specializing in life sciences, has partnered with Veeda Lifesciences (search), a global contract research organization, to establish a dedicated Host Cell Protein (search) (HCP) Services Center in Bengaluru, India. The collaboration aims to support biopharmaceutical companies in reducing development risks and meeting regulatory standards for novel biologics (search) and biosimilars (search) through advanced impurity analysis and HCP testing services.
Strategic Partnership for Biologics Quality Assurance
The newly established center will serve as a comprehensive analytical hub for manufacturers, researchers, and academic institutions. Located within Veeda's facility and supported by Cytiva (search)'s technology, the center will generate regulatory-ready data for impurity analysis across recombinant proteins, therapeutic monoclonal antibodies (search), vaccines (search), and related modalities.
"We are delighted to partner with Cytiva (search) to bring deeper scientific insights to biologics (search) manufacturers and enable more robust characterization of biopharmaceutical products," said Dr. Mahesh Bhalgat, Group CEO and managing director of Veeda Lifesciences (search). "Analytical data is central to product approvals, and our collaboration strengthens the foundation of regulatory approvals of biosimilars (search)."
Advanced Analytical Capabilities
The center will utilize multiple attribute DIGE (differential gel electrophoresis) techniques to streamline workflows and enhance the speed and accuracy of analysis. Key services include HCP coverage, characterization and quantification assays, which are essential for detecting impurities that could compromise product quality and patient safety.
Host cell proteins are process-related impurities from the cells used to manufacture biologics (search). Even at trace levels, HCP residues can cause toxicity, immune reactions, and affect drug stability. The collaboration will employ advanced analytical methods combining ELISA and mass spectrometry to help companies assess process effectiveness and ensure quality.
Industry Context and Market Demand
This initiative aligns with findings from Cytiva (search)'s 2025 Biopharma Index, which highlights growing demand for analytical and digital tools that improve assurance, regulatory review, and process control. These tools help companies scale production, reduce batch failures, and deliver critical medicines faster.
"This new centre is a bold step toward accelerating innovation and advancing therapeutics," said Manoj Kumar R Panicker, general manager of South Asia at Cytiva (search). "It represents what's possible when science, industry, and purpose unite to shape the future of biopharma excellence."
Supporting India's Bioeconomy Growth
As India's bioeconomy moves toward the USD 300 billion mark by 2030, initiatives such as this reinforce the country's position as a trusted hub for biologics (search) research, manufacturing, and innovation. The center's focus on regulatory compliance and quality assurance positions it to support both domestic and international biopharmaceutical development efforts.